Correction (DOI:10.1016/j.ahj.2008.11.007);Heparin/PF4 antibodies formation after heparin treatment: Temporal aspects and long-term follow-up

American Heart Journal

Volumn 157, Issue 3, 2009, Pages 589-595

  Mattioli, Anna Vittoria ^a   Bonetti, Lorenzo ^b   Zennaro, Mauro ^c   Ambrosio, Giuseppe ^d   Mattioli, Giorgio ^e  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Pavullo Hospital   (Italy)

^c Azienda Ospedaliera Baggiovara   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e National Institute of Cardiovascular Disease   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; THROMBOSIS;

EID: 60649101800     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.07.019     Document Type: Erratum

References (29)

1. Warkentin T.E., Sheppard J.O., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 (2000) 1703-1708
2. Das P., Ziada K., Steinhubl S.R., et al. Heparin-induced thrombocytopenia and cardiovascular diseases. Am Heart J 152 (2006) 19-26
3. Mattioli A.V. Prevalence of Anti-PF4/heparin antibodies and the HIT syndrome in cardiovascular medicine. Sem Thromb Hemost 30 (2004) 291-295
4. Mattahi W.H. Treatment of heparin-induced thrombocytopenia in cardiovascular patients. Expert Opin Pharmacother 7 (2006) 267-276
5. Warkentin T.E. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 82 (1999) 439-447
6. Oliveira G.B.F., Crespo E.M., Becker R.C., et al., for the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 168 1 (2008) 94-102
7. Williams R.T., Damaraju L.V., Mascelli M.A., et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107 (2003) 2307-2312
8. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
9. Cines D.B., Kaywin P., Bina M., et al. Heparin-associated thrombocytopenia. N Engl J Med 303 (1980) 788-795
10. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 334 (2001) 1286-1292
11. Warkentin T.E., and Heddle N.M. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2 (2003) 148-157
12. Mattioli A.V., Bonetti L., Sternieri S., et al. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 1 (2000) 39-42
13. Nashef S.A.M., Roques F., Michel P., et al., the EuroSCORE Study Group. European System for Cardiac Operative Risk Evaluation (EuroSCORE). Eur J Cardiothorac Surg 16 (1999) 9-13.
14. Zwicker J.I., Uhl L., Huang W.Y., et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2 (2004) 2133-2137
15. Ohman E.M., Granger C.B., Rice L., et al. Identification, diagnosis, and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee. J Thromb Thrombolysis 19 (2005) 11-19
16. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 311S-317S
17. Menajovsky L.B. Heparin-induced thrombocytopenia: clinical manifestations and management strategies. Am J Med 118 (2005) 21S-30S
18. Bauer K.A. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost 28 Suppl 2 (2002) 15-24
19. Khairy M., Lasne D., Brohard-Bohn B., et al. A new approach in the study of the molecular and cellular events implicated in heparin-induced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 85 (2001) 1090-1096
20. Potzsch B., Klovekorn W.P., and Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343 (2000) 515-518
21. Rice L., Attisha W.K., Drexler A., et al. Delayed onset heparin-induced thrombocytopenia. Ann Intern Med 136 (2002) 210-215
22. Warkentin T.E., and Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 (2001) 502-506
23. Kuitunen A., Suojaranta-Ylinen R., Raivio P., et al. Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Cardiothorac Vasc Anest 21 (2007) 18-22
24. Pouplard C., May M.A., Regina S., et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 128 (2005) 837-841
25. Bennett-Guerrero E., Slaughter T.F., White W.D., et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130 (2005) 1567-1572
26. Greinacher A., Farner B., Kroll H., et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 94 (2005) 132-135
27. Warkentin T.E. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 35 (1998) 9-16
28. Warkentin T.E., Chong B.H., and Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79 (1998) 1-7
29. Bolton F.G., and Young R.V. Observations on cases of thrombocytopenic purpura due to quinidine, sulphamezathine, and quinidine. J Clin Pathol 6 (1953) 320-323